<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="publisher-id">MEDI</journal-id>
      <journal-title-group>
        <journal-title>Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0025-7974</issn>
      <issn pub-type="epub">1536-5964</issn>
      <publisher>
        <publisher-name>Wolters Kluwer Health</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26469919</article-id>
      <article-id pub-id-type="pmc">4616798</article-id>
      <article-id pub-id-type="doi">10.1097/MD.0000000000001778</article-id>
      <article-id pub-id-type="art-access-id">01778</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>4800</subject>
        </subj-group>
        <subj-group>
          <subject>Research Article</subject>
          <subject>Clinical Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A Pediatric Acute Promyelocytic Leukemia With a Rare Karyotype of ider(17)(q10)t(15;17) and Favorable Outcome</article-title>
        <subtitle>A Case Report</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>He</surname>
            <given-names>Yanli</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Ping</given-names>
          </name>
          <degrees>BSc</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liang</surname>
            <given-names>Kaiwei</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Xiangjun</given-names>
          </name>
          <degrees>MSc</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Du</surname>
            <given-names>Wen</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Juan</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>Yanjie</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bai</surname>
            <given-names>Yan</given-names>
          </name>
          <degrees>MSc</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Wei</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Xiaoqing</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jin</surname>
            <given-names>Runming</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Min</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>Jine</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Staege.</surname>
            <given-names>Martin</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff>From the Center for Stem Cell Research and Application, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (YH, KL, XC, WD, JL, YH, WL, XL, JZ); Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (PW); Department of Pediatric, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (YB, RJ); and Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (MZ).</aff>
      <author-notes>
        <corresp>Correspondence: Jine Zheng, 1277 Jiefang Avenue, Center for Stem Cell Research and Application, Union Hospital, Wuhan, China (e-mail: <email>enij@sina.com</email>).</corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <volume>94</volume>
      <issue>41</issue>
      <elocation-id>e1778</elocation-id>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>5</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>18</day>
          <month>8</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>9</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2015 Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0">
          <license-p>This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="medi-94-e1778.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>Acute promyelocytic leukemia (APL) is a specific malignant hematological disorder with a diagnostic hallmark of chromosome translocation t(15;17)(q22;q21). As a very rare secondary cytogenetic aberration in pediatric APL, ider(17q) (q10)t(15;17) was suggested to be a poor prognostic factor based on previous case reports.</p>
        <p>Here, we report a pediatric APL case with a rare karyotype of ider(17)(q10)t(15;17). Bone marrow aspiration, immunophenotyping, molecular biology, cytogenetic, and fluorescence in situ hybridization (FISH) analyses were performed at initial diagnosis and during the treatment.</p>
        <p>A 6-year-old boy was brought to our hospital with the chief complaint of bleeding gums twice and intermittent fever for 3 days in January 2013. He was diagnosed as low-risk APL according to the 2012 NCCN guideline on APL, with the expression of PML-RARA (bcr3 subtype) and the karyotype of 46,XY, der(15)t(15;17)(q22;q21),ider(17)(q10)t(15;17), which was further verified by FISH. The patient was treated through combination all-trans retinoic acid (ATRA) and arsenic with daunorubicin according to the 2012 NCCN guideline for APL. Continuous hematological completed remission (HCR) and major molecular remission (MMR) were achieved with normal karyotype for &gt;28 months after induction chemotherapy.</p>
        <p>Different from previously reported cases, this pediatric APL patient with ider(17)(q10)t(15;17) displays favorable clinical outcomes, which might be related to the low-risk classification and arsenic treatment during the treatment. It suggests that ider(17)(q10)t(15;17) may not be the sole determinant for worse outcomes in pediatric APL and implies that more contributed factors should be considered for pediatric APL prognosis.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The fusion gene PML-RARA generated from chromosome translocation t(15;17)(q22;q21) has been identified as a distinguished marker for acute promyelocytic leukemia (APL).<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Classic cytogenetics combined with florescence in situ hybridization (FISH) indicates 90% of typical t(15;17) and some rare case of atypical translocations such as t(5;17), t(11;17), and dup(17)(q21q23) in APL.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> In the past decades, owing to the utilization of all-trans-retinoic acid (ATRA) in combination with arsenic and other chemotherapies, APL has been one of most curable leukemia types.<sup><xref rid="R3" ref-type="bibr">3</xref>&#x2013;<xref rid="R5" ref-type="bibr">5</xref></sup> As high as 95% of newly diagnosed APL patients with the PML-RARA fusion gene could achieve completed remission (CR) after the treatments, in which &#x223C;80% reaches long-term event-free survival. However, a small population of APL patients still show poor outcomes after post-remission chemotherapy, which may be attributed to some featured genetic abnormalities as well as changes in treatment response, relapse, and clinical pathological characters.<sup><xref rid="R6" ref-type="bibr">6</xref>&#x2013;<xref rid="R9" ref-type="bibr">9</xref></sup></p>
      <p>The ider(17)(q10)t(15;17)(q22;q12)<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R10" ref-type="bibr">10</xref>&#x2013;<xref rid="R15" ref-type="bibr">15</xref></sup> is one of the rare secondary genetic abnormalities in APL. To the best of our knowledge, only 4 pediatric APL cases with ider(17)(q10)t(15;17)(q22;q12) were reported in the literature and all of them died in 1 to 21 months after diagnosis.<sup><xref rid="R16" ref-type="bibr">16</xref>&#x2013;<xref rid="R19" ref-type="bibr">19</xref></sup> These data suggest that ider(17)(q10)t(15;17)(q22;q12) is likely to be a poor prognostic marker for pediatric APL. Different from previous reports, we first report a pediatric APL case with the rare karyotype of ider(17)(q10)t(15;17), which still remains CR for 28 months until now.</p>
    </sec>
    <sec sec-type="materials|methods">
      <title>MATERIALS AND METHODS</title>
      <sec sec-type="cases">
        <title>Case Report</title>
        <p>A 6-year-old boy was brought to our hospital with the chief complaint of bleeding gums twice and intermittent fever for 3 days in January 2013. He had a fever of 38.2 Celsius, multiple cervical lymphadenopathy, scattered bleeder in both lower limbs and enlarged liver at 2&#x200A;cm of the subcostal. No special contact, allergies, medicine, or family history were present. No more positive signs were found. The initial blood count showed pancytopenia (Hb, 95&#x200A;g/L; red blood cell count, 3.18&#x200A;&#xD7;&#x200A;10<sup>12</sup>/L; platelet count, 57&#x200A;&#xD7;&#x200A;10<sup>9</sup>/L; and white blood cell count, 2.23&#x200A;&#xD7;&#x200A;10<sup>9</sup>/L). The bone marrow morphology displayed a hypercellular marrow with increased abnormal promyelocytes, which were variable in the cell size and nucleolus, rich in cytoplasm and varying granules, and visible of round or oval, distorted, folded nucleus, accounting for 87.5% of all nucleated cells. Bone marrow specimens were also positive for myeloperoxidase and nonspecific esterase staining (Fig. <xref ref-type="fig" rid="F1">1</xref>). Flow cytometry analysis (Fig. <xref ref-type="fig" rid="F2">2</xref>) with the bone marrow showed that &#x223C;91.5% of blasts were strongly positive for CD9, CD13, CD15, CD33, CD45, CD64, CD123, Myeloperoxidase, with partial expression of CD38, CD117, HLA-DR, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD14, CD16, CD19, CD20, CD22, and CD34, whereas CD56, CD71, GlyA, cCD79a, cCD3, TdT were negative (Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>). Cytogenetic studies showed a karyotype of 46,XY, der(15)t(15;17)(q22;q21), ider(17)(q10)t(15;17) according to ISCN2009<sup><xref rid="R20" ref-type="bibr">20</xref></sup> (Fig. <xref ref-type="fig" rid="F3">3</xref>A and B). Fluorescence in situ hybridization (FISH) with Vysis LSI PML/RAR&#x3B1; dual color, dual fusion translocation probe (Abbott Molecular, IL) revealed nuc ish (nuclear in situ hybridization) (PML&#x200A;&#xD7;&#x200A;4)(RARA&#x200A;&#xD7;&#x200A;4)(PML con RARA&#x200A;&#xD7;&#x200A;3)[400] (Fig. <xref ref-type="fig" rid="F3">3</xref>C and D). The fusion PML-RARA gene in this patient was furthered characterized as bcr3 subtype by real-time quantitative polymerase chain reaction (RT-qPCR). Therefore, the patient was diagnosed as APL according to bone marrow morphology, immunophenotyping, cytogenetics, and molecular biology studies. Subsequently, the patient was administrated with induction chemotherapy consisting of ATRA at a dose of 45&#x200A;mg/m<sup>2</sup>/d for 33 days, arsenic trioxide 0.15&#x200A;mg/kg/d for 27 days, and daunorubicin 60&#x200A;mg/m<sup>2</sup>/d for 3 days.</p>
        <fig id="F1" position="float">
          <label>FIGURE 1</label>
          <caption>
            <p>Bone marrow morphology at initial diagnosis. Bone marrow aspiration showed a hypercellular marrow with increased abnormal promyelocytes, which were variable in the cell size and nucleolus, rich in cytoplasm and varying granules, and visible of round or oval, distorted, folded nucleus.</p>
          </caption>
          <graphic xlink:href="medi-94-e1778-g001"/>
        </fig>
        <fig id="F2" position="float">
          <label>FIGURE 2</label>
          <caption>
            <p>Immunophenotyping of bone marrow at initial diagnosis. In the dot plot of CD45/side scatter (SSC), the abnormal APL leukemia cells were continuously distributed from immature to mature granulocytes cells area. The abnormal promyelocytes comprised 91.5% of the nucleated cells and expressed CD9, CD13, CD15, CD33, CD45, CD64, CD123, Myeloperoxidase (MPO), also with partial expression of CD38 and CD117. APL&#x200A;=&#x200A;acute promyelocytic leukemia.</p>
          </caption>
          <graphic xlink:href="medi-94-e1778-g002"/>
        </fig>
        <table-wrap id="T1" position="float">
          <label>TABLE 1</label>
          <caption>
            <p>Comparison Between Previous 4 Reports and Present Study With ider(17)(q10)t(15;17)(q22;q12) Positive APL</p>
          </caption>
          <graphic xlink:href="medi-94-e1778-g003"/>
        </table-wrap>
        <table-wrap id="T2" position="float">
          <label>TABLE 2</label>
          <caption>
            <p>The Percentages of the Detected Antigens in this Patient by Flow Cytometry</p>
          </caption>
          <graphic xlink:href="medi-94-e1778-g004"/>
        </table-wrap>
        <fig id="F3" position="float">
          <label>FIGURE 3</label>
          <caption>
            <p>Karyotype and FISH analysis at initial diagnosis. A: the karyotyping from 20 bone marrow metaphase cells showed 46,XY,der(15)t(15;17)(q22;q21),ider (17)(q10)t(15;17). The arrows indicate abnormal chromosomes. B: one of the metaphase karyograms of the bone marrow cells at initial diagnosis. The arrows indicate der(15) and ider(17)(q10)t(15;17). C: the FISH study using an LSI PML-RARA dual-color, dual-fusion translocation probe (Abbott Molecular/Vysis) at diagnosis. The arrows indicate positive PML-RARA fusion signals (3 fusion signals in a cell). D: karyotyping and PML-RARA FISH analysis in the same metaphase cell. FISH&#x200A;=&#x200A;fluorescence in situ hybridization.</p>
          </caption>
          <graphic xlink:href="medi-94-e1778-g005"/>
        </fig>
        <p>After the induction chemotherapy, the blood cell counts came back to normal levels and bone marrow aspirate showed hematological completed remission (HCR) but not major molecular remission (MMR) with detection out of PML-RARA by RT-qPCR. Then, one cycle of DA regimen (Daunorubicin 60&#x200A;mg/m<sup>2</sup>/d, d1-3;cytarabine 200&#x200A;mg/m<sup>2</sup>/d, d1-7) and another cycle of DA regimen (Daunorubicin 45&#x200A;mg/m<sup>2</sup>/d, d1-3;cytarabine 1&#x200A;g/m<sup>2</sup>/12&#x200A;h, d1-4) were administrated to the patient as the consolidation chemotherapy. After the consolidation therapy, the patient achieved MMR (the PML-RARA was undetectable by RT-qPCR) under HCR. Maintenance chemotherapy was still continued following the consolidation chemotherapy according to the 2012 NCCN guideline for APL. No serious side reactions occurred in the chemotherapy process. During and after the maintenance chemotherapy, this patient was always under persistent MMR and HCR without any clinical symptoms or signs till now.</p>
        <p>The patient provided written informed consent for the publication of this case details and the consent procedure was approved by the ethic committee for Drug Clinical Trial of Huazhong University of Science and Technology.</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The ider(17)(q10)t(15;17) is a derived isochromosomal abnormality on the long arm of chromosome 17 with APL unique reciprocal translocation of t(15;17). It is also a rare cytogenetic abnormality in APL. From January 2013 to December 2014, we detected 12 cases with the karyotype of ider(17) (q10)t(15;17) in 635 APL patients with t(15;17) in our center. They are at the average age of 29.6 years (from 6 to 75 years old). The incidence of ider(17) (q10)t(15;17) in our center is 1.89%, which is consistent with previous report.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Although previous studies<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> reported that the ider(17q)(q10)t(15;17) had a slightly higher frequency in APL patients with PML-RARA bcr1 subtype, which might be related to delayed CR and lower sensitivity to ATRA treatment, we found no significant correlation between ider(17) (q10)t(15;17) and 3 isoforms of PML-RARA gene (bcr1, bcr 2 and bcr3 subtypes) in our center, which may be caused by the rarity of ider(17) (q10)t(15;17) since we only have 12 ider(17) (q10)t(15;17) positive cases until now.</p>
      <p>To the best of our knowledge, only 4 pediatric APL cases with the ider(17q)(q10)t(15;17) have been reported in the literature so far.<sup><xref rid="R21" ref-type="bibr">21</xref>&#x2013;<xref rid="R23" ref-type="bibr">23</xref></sup> The role of the ider(17q)(q10)t(15;17) in APL is still an ongoing investigation and all of the previous studies considered it as a poor prognosis maker for APL especially in pediatric APL patients.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> As shown in Table <xref ref-type="table" rid="T1">1</xref>, no matter the variable clinical and laboratory features as wells as different treatments, 1 of the 4 reported pediatric patients did not achieve CR at all and died in the first month from the initial diagnosis, whereas the remained 3 cases relapsed and died within 13 to 21 survival months.<sup><xref rid="R16" ref-type="bibr">16</xref>&#x2013;<xref rid="R19" ref-type="bibr">19</xref></sup> Interestingly, Hu and colleagues<sup><xref rid="R21" ref-type="bibr">21</xref></sup> showed that the ider(17)(q10)t(15;17) had a proliferation and growth advantage, which might be mediated by loss of a tumor suppressor TP53 allele. However, no drug-sensitive analysis has been performed in the ider(17)(q10)t(15;17) positive clones and the detailed role of TP53 copy number variation in these clones is still mysterious. The sensitivity of these clones containing the ider(17)(q10)t(15;17) to ATRA, arsentic trioxide and other chemotherapy drugs is still unknown and need further studies.</p>
      <p>Interestingly, the case we presented here displayed encouraging clinical outcomes until now. He was treated with both ATRA and arsenic and achieved HCR after induction therapy and MMR after consolidation therapy. After consolidation chemotherapy, this patient was still under continuous HCR and MMR for &gt;28 months until now by detection of MRD every 3 months. Besides, no serious complications and side effects (such as the ATRA syndrome) of chemotherapeutic agents occurred during and after serials of therapies. This is the first case report of pediatric APL with ider(17)(q10)t(15;17) showing favorable outcomes after chemotherapy. It suggests that the ider(17)(q10)t(15;17) may not be the sole determinants for worse outcomes in pediatric APL and more contributed factors need to be considered for pediatric APL prognosis.</p>
      <p>As an inference, we think the encouraging clinical outcomes from this case may be attributed to 2 important factors. First, this patient was classified in the low-risk group at the initial diagnosis stage according to the 2012 NCCN guideline for APL. The risk classification is very important for APL, especially pediatric APL, and it correlates very well with the therapeutic effects, clinical outcomes, and relapse. Basically, low-risk classification means better response to treatment and less relapse. Second, we think the patient may also benefit from the early usage of arsenic trioxide. As one of the most famous Chinese traditional medicaments, arsenic trioxide has been shown powerful therapeutic effects in APL and has been the standard treatment for APL patients in both induction and maintenance chemotherapies. Combination of ATRA and arsenic also has synergistic effects in APL patients during induction therapy due to their different pharmacology targets (ATRA targets RAR&#x3B1; and arsenic targets PML).<sup><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> For the 4 previously reported pediatric APL cases with the ider(17)(q10)t(15;17), 2 of them<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> were reported in 1986 and 1987, which were before the starting of ATRA treatment in 1988. The remaining 2 cases also did not involve the combination of ATRA and arsenic in the induction chemotherapy.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> Therefore, we infer that the patient reported here may benefit from the combination of ATRA and arsenic in the induction chemotherapy. However, more case reports and systematic analysis are needed to study the role of ATRA and arsenic in the treatment of pediatric APL patients with the ider(17)(q10)t(15;17).</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="abbr">
        <p>Abbreviations: APL = acute promyelocytic leukemia, ATRA = all-trans retinoic acid, CR = completed remission, FISH = fluorescene in situ hybridization, HCR = hematological completed remission, MMR = major molecular remission, MRD = minimal residual disease, NCCN = national comprehensive cancer network, RT-qPCR = real time quantitative polymerase chain reaction.</p>
      </fn>
      <fn fn-type="equal">
        <p>YH and PW equally contributed to this study.</p>
      </fn>
      <fn fn-type="con">
        <p>Authors and their contributions: YH performed study in cytogenetic, FISH and flow cytometry, wrote the paper. PW performed study in clinical lab tests and molecular biology. KL provided assistant to perform the experiment and modified the paper. XC analyzed cytogenetic data. WD analyzed flow cytometric data. JL analyzed FISH data. YH contributed important reagents. YB collected clinical data. WL analyzed morphological data. XL analyzed molecular data. RJ clinical guiding. MZ Clinical guiding and paper modification. JZ designed the study and wrote paper.</p>
      </fn>
      <fn fn-type="supported-by">
        <p>This research was supported by grants-in-aid from the National Young Scientist's Programs of China (No. 81100356, 81202093, 81201552).</p>
      </fn>
      <fn fn-type="conflict">
        <p>The authors have no conflicts of interest to disclose.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Swerdlow</surname><given-names>SH</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Harris</surname><given-names>NL</given-names></name><etal/></person-group>
<article-title>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues</article-title>. <edition>4th ed.</edition><year>2008</year>; <publisher-loc>Lyon</publisher-loc>: <publisher-name>World Health Organization</publisher-name>, <comment>112&#x2013;114</comment>.</mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>WL</given-names></name><name><surname>Xiong</surname><given-names>SM</given-names></name><etal/></person-group>
<article-title>Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia</article-title>. <source><italic>Leukemia</italic></source>
<year>2001</year>; <volume>15</volume>:<fpage>1359</fpage>&#x2013;<lpage>1368</lpage>.<pub-id pub-id-type="pmid">11516096</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Qiao</surname><given-names>B</given-names></name><name><surname>Panageas</surname><given-names>KS</given-names></name><etal/></person-group>
<article-title>Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid</article-title>. <source><italic>Blood</italic></source>
<year>2011</year>; <volume>118</volume>:<fpage>1248</fpage>&#x2013;<lpage>1254</lpage>.<pub-id pub-id-type="pmid">21653939</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>BL</given-names></name></person-group>
<article-title>Arsenic trioxide in acute promyelocytic leukemia: potion not poison</article-title>. <source><italic>Expert Rev Anticancer Ther</italic></source>
<year>2011</year>; <volume>11</volume>:<fpage>1317</fpage>&#x2013;<lpage>1319</lpage>.<pub-id pub-id-type="pmid">21929304</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tallman</surname><given-names>MS</given-names></name><name><surname>Altman</surname><given-names>JK</given-names></name></person-group>
<article-title>Curative strategies in acute promyelocytic leukemia</article-title>. <source><italic>Hematology Am Soc Hematol Educ Program</italic></source>
<year>2008</year>; <fpage>391</fpage>&#x2013;<lpage>399</lpage>.<pub-id pub-id-type="pmid">19074116</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Cho</surname><given-names>SY</given-names></name><name><surname>Lim</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>A rare case of microgranular acute promyelocytic leukemia associated with ider(17)(q10)t(15;17) in an old-age patient</article-title>. <source><italic>Korean J Lab Med</italic></source>
<year>2011</year>; <volume>31</volume>:<fpage>86</fpage>&#x2013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">21474981</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cervera</surname><given-names>J</given-names></name><name><surname>Montesinos</surname><given-names>P</given-names></name><name><surname>Hernandez-Rivas</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy</article-title>. <source><italic>Haematologica</italic></source>
<year>2010</year>; <volume>95</volume>:<fpage>424</fpage>&#x2013;<lpage>431</lpage>.<pub-id pub-id-type="pmid">19903674</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poire</surname><given-names>X</given-names></name><name><surname>Moser</surname><given-names>BK</given-names></name><name><surname>Gallagher</surname><given-names>RE</given-names></name><etal/></person-group>
<article-title>Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype</article-title>. <source><italic>Leuk Lymphoma</italic></source>
<year>2014</year>; <volume>55</volume>:<fpage>1523</fpage>&#x2013;<lpage>1532</lpage>.<pub-id pub-id-type="pmid">24160850</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Mei</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid</article-title>. <source><italic>Ann Hematol</italic></source>
<year>2011</year>; <volume>90</volume>:<fpage>1493</fpage>&#x2013;<lpage>1494</lpage>.<pub-id pub-id-type="pmid">21431323</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manola</surname><given-names>KN</given-names></name><name><surname>Karakosta</surname><given-names>M</given-names></name><name><surname>Sambani</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Isochromosome der(17)(q10)t(15;17) in acute promyelocytic leukemia resulting in an additional copy of the RARA-PML fusion gene: report of 4 cases and review of the literature</article-title>. <source><italic>Acta Haematol</italic></source>
<year>2010</year>; <volume>123</volume>:<fpage>162</fpage>&#x2013;<lpage>170</lpage>.<pub-id pub-id-type="pmid">20224268</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Bian</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>The short isoform of the long-type PML-RARA fusion gene in acute promyelocytic leukaemia lacks sensitivity to all-trans-retinoic acid</article-title>. <source><italic>Br J Haematol</italic></source>
<year>2013</year>; <volume>162</volume>:<fpage>93</fpage>&#x2013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">23627671</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashur-Fabian</surname><given-names>O</given-names></name><name><surname>Trakhtenbrot</surname><given-names>L</given-names></name><name><surname>Dominissini</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>The presence of a single PML-RARA isoform lacking exon 5 in FISH-negative APL samples</article-title>. <source><italic>Leukemia</italic></source>
<year>2008</year>; <volume>22</volume>:<fpage>200</fpage>&#x2013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">17960172</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>HR</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Miao</surname><given-names>KR</given-names></name><etal/></person-group>
<article-title>Clinical and laboratory studies of an acute promyelocytic leukemia patient with double ider(17q) chromosome aberration</article-title>. <source><italic>Cancer Genet Cytogenet</italic></source>
<year>2008</year>; <volume>184</volume>:<fpage>74</fpage>&#x2013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">18558295</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>TS</given-names></name><name><surname>So</surname><given-names>CC</given-names></name><name><surname>Hui</surname><given-names>KC</given-names></name><etal/></person-group>
<article-title>Diagnostic utility of dual fusion PML/RARalpha translocation DNA probe (D-FISH) in acute promyelocytic leukemia</article-title>. <source><italic>Oncol Rep</italic></source>
<year>2007</year>; <volume>17</volume>:<fpage>799</fpage>&#x2013;<lpage>805</lpage>.<pub-id pub-id-type="pmid">17342318</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>GY</given-names></name><name><surname>Christina</surname><given-names>S</given-names></name><name><surname>Tien</surname><given-names>SL</given-names></name><etal/></person-group>
<article-title>Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia</article-title>. <source><italic>Cancer Genet Cytogenet</italic></source>
<year>2005</year>; <volume>159</volume>:<fpage>129</fpage>&#x2013;<lpage>136</lpage>.<pub-id pub-id-type="pmid">15899384</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>WC</given-names></name><name><surname>Tang</surname><given-names>JL</given-names></name><name><surname>Yao</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment</article-title>. <source><italic>Leukemia</italic></source>
<year>1997</year>; <volume>11</volume>:<fpage>921</fpage>&#x2013;<lpage>928</lpage>.<pub-id pub-id-type="pmid">9204969</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Yoon</surname><given-names>HS</given-names></name><name><surname>Cho</surname><given-names>SY</given-names></name><etal/></person-group>
<article-title>ider(17)(q10)t(15;17) associated with relapse and poor prognosis in a pediatric patient with acute promyelocytic leukemia</article-title>. <source><italic>Cancer Genet Cytogenet</italic></source>
<year>2010</year>; <volume>201</volume>:<fpage>116</fpage>&#x2013;<lpage>121</lpage>.<pub-id pub-id-type="pmid">20682396</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prigogina</surname><given-names>EL</given-names></name><name><surname>Fleischman</surname><given-names>EW</given-names></name><name><surname>Puchkova</surname><given-names>GP</given-names></name><etal/></person-group>
<article-title>Chromosomes in acute nonlymphocytic leukemia</article-title>. <source><italic>Hum Genet</italic></source>
<year>1986</year>; <volume>73</volume>:<fpage>137</fpage>&#x2013;<lpage>146</lpage>.<pub-id pub-id-type="pmid">3721500</pub-id></mixed-citation>
      </ref>
      <ref id="R19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmers</surname><given-names>RN</given-names></name><name><surname>Webber</surname><given-names>LM</given-names></name><name><surname>Shannon</surname><given-names>MF</given-names></name><etal/></person-group>
<article-title>Localization of the G-CSF gene on chromosome 17 proximal to the breakpoint in the t(15;17) in acute promyelocytic leukemia</article-title>. <source><italic>Blood</italic></source>
<year>1987</year>; <volume>70</volume>:<fpage>330</fpage>&#x2013;<lpage>332</lpage>.<pub-id pub-id-type="pmid">2439153</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="editor"><name><surname>Shaffer</surname><given-names>LG</given-names></name><name><surname>Slovak</surname><given-names>ML</given-names></name><name><surname>Campbell</surname><given-names>LJ</given-names></name></person-group> (eds). ISCN 2009: <source>An International System for Human Cytogenetic Nomenclature (2009). Karger Medical and Scientific Publishers</source>, <year>2008</year>:<volume>45</volume>&#x2013;<lpage>46</lpage>.</mixed-citation>
      </ref>
      <ref id="R21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Ai</surname><given-names>G</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>An ider(17)(q10)t(15;17) with spliced long-type PML-RARA fusion transcripts in a case of acute promyelocytic leukemia</article-title>. <source><italic>Cancer Genet</italic></source>
<year>2014</year>; <volume>207</volume>:<fpage>253</fpage>&#x2013;<lpage>257</lpage>.<pub-id pub-id-type="pmid">25052141</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoch</surname><given-names>C</given-names></name><name><surname>Haase</surname><given-names>D</given-names></name><name><surname>Haferlach</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients</article-title>. <source><italic>Br J Haematol</italic></source>
<year>1996</year>; <volume>94</volume>:<fpage>493</fpage>&#x2013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">8790148</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okoshi</surname><given-names>Y</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Kono</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Effect of additional chromosomal abnormalities in acute promyelocytic leukemia treated with all-trans-retinoic acid: a report of 17 patients</article-title>. <source><italic>Int J Hematol</italic></source>
<year>2001</year>; <volume>73</volume>:<fpage>496</fpage>&#x2013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">11503965</pub-id></mixed-citation>
      </ref>
      <ref id="R24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SJ</given-names></name><name><surname>Zhou</surname><given-names>GB</given-names></name><name><surname>Zhang</surname><given-names>XW</given-names></name><etal/></person-group>
<article-title>From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia</article-title>. <source><italic>Blood</italic></source>
<year>2011</year>; <volume>24</volume>:<fpage>6425</fpage>&#x2013;<lpage>6437</lpage>.<pub-id pub-id-type="pmid">21422471</pub-id></mixed-citation>
      </ref>
      <ref id="R25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XW</given-names></name><name><surname>Yan</surname><given-names>XJ</given-names></name><name><surname>Zhou</surname><given-names>ZR</given-names></name><etal/></person-group>
<article-title>Arsenic trioxide controls the fate of the PML-RAR alpha oncoprotein by directly binding PML</article-title>. <source><italic>Science</italic></source>
<year>2010</year>; <volume>328</volume>:<fpage>240</fpage>&#x2013;<lpage>243</lpage>.<pub-id pub-id-type="pmid">20378816</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
